Moreover, the native TRP2 and gp100 antigens mostly failed to induce CD8+ T cell responses, possibly suggesting that modified antigens, or peptide antigens containing tumor-associated mutations, will be needed to drive significant tumor-specific responses from a CMV backbone [62,63]. Here, CD8A is linked to neoplasm.